HLA-DRBI*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis

C. Fusco, V. Andreone, G. Coppola, V. Luongo, F. Guerini, E. Pace, C. Florio, G. Pirozzi, R. Lanzillo, P. Ferrante, P. Vivo, M. Mini, M. Macrì, G. Orefice, Maria Luisa Lombardi

Research output: Contribution to journalArticlepeer-review


Background: Copolymer 1 (Cop-1) is a random synthetic amino acid copolymer, effective in the treatment of the relapsing-remitting form of MS (RRMS). In vitro and in vivo studies suggest that the mechanism of Cop-1 involves its binding to major histocompatibility complex class II molecules as an initial step. Objective: To assess a possible relationship between human leukocyte antigen (HLA) alleles and response to Cop-1 therapy. Methods: Eighty-three patients with RRMS, 44 treated with Cop-1 and 39 with interferon β-1a (IFNβ-1a) for 2 years, were typed by molecular methods for HLA class II genes and subgrouped according to clinical outcome. Results: Data have shown a possible positive correlation between presence of DRB1*1501 and response to Cop-1 therapy (p = 0.008). No relationship between HLA alleles and therapy has been found in IFNβ-1a treated patients. Conclusions: Results suggest that DRB1*1501 might be relevant for the clinical outcome in Cop-1 treated patients and, if confirmed in larger studies, it could be helpful in the selection of RRMS patients for different therapeutic options.

Original languageEnglish
Pages (from-to)1976-1979
Number of pages4
Issue number11
Publication statusPublished - Dec 11 2001

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'HLA-DRBI*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis'. Together they form a unique fingerprint.

Cite this